RNA Interference News and Research

RSS

Researchers identify new genes necessary for embryonic development

Researchers at New York University and the medical schools at Harvard and Yale universities have identified new genes necessary for embryonic development, according to findings published in the latest issue of Genome Research.

31 Jan 2005

Scientists discover that microRNAs regulate thousands of human genes

For many years, DNA and proteins have been viewed as the real movers and shakers in genomic studies, with RNA seen as little more than a messenger that shuttles information between the two.

16 Jan 2005

First program to apply RNA interference (RNAi) technology to asthma

Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.

7 Jan 2005

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

The hopes of many that ALS (commonly referred to as Lou Gehrig's disease) will one day be a disease of the past, studied in medical textbooks, conquered by the dedication of those who have worked tirelessly to eradicate it might be realized in our lifetime.

6 Dec 2004

Temperature sensing protein implicated in mediating thermotaxis

The songwriter Noel Coward once declared that only mad dogs and Englishmen went out in the midday sun. MIT biologists Mark Rosenzweig, Paul Garrity and their colleagues now have a third candidate for the lyric—fruit flies with defects in a gene called dTrpA1.

4 Dec 2004

Research opens up new avenues to diagnosis and treat Lyme disease

Researchers at Yale School of Medicine have identified a Lyme disease receptor called TROSPA that is used by disease agents to invade ticks.

14 Nov 2004

Blocking gene opens avenues for treating prostate cancer

Cancer Research UK scientists in Oxford have found a new way to make prostate cancer succumb more readily to currently used treatments.

22 Oct 2004

New link in the growth of Ewing’s sarcoma

To develop new therapeutic approaches to cancer, it is essential to understand the long and extremely complex process that underlies it, in other words the various stages of cancer development from the initial mutation to the tumor.

23 Sep 2004

RNAi enlisted in hunt for prawn vaccines

CSIRO researchers are using a biological phenomenon called RNA interference (RNAi) in an effort to develop a major biotechnological breakthrough for the aquaculture industry - vaccines for common prawn diseases.

16 Sep 2004

Advances in gene silencing on the agenda

Recent advances in using 'RNA interference' (RNAi) to improve plant, animal and human health will be the major focus of the CSIRO-hosted Horizons in Livestock Sciences Conference on the Gold Coast from 12-15 September.

8 Sep 2004

Research could lead to ways to prevent arrhythmias

The worm C. elegans seems an unlikely candidate for studies related to cardiac arrhythmias. After all, the microscopic organism doesn't even have a heart.

20 Aug 2004

Study on RNAi technology targeting neurodegenerative diseases

Sirna Therapeutics has announced the publication of preclinical studies evaluating RNA interference-based therapies for a class of inherited neurodegenerative diseases of the central nervous system (CNS) in the current issue of Nature Medicine.

16 Aug 2004

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010.

9 Aug 2004

8.5 million Euros to address a fundamental question on mitosis: How is cell division regulated?

Scientists at the European Molecular Biology Laboratory (EMBL) join forces with top scientists from eleven research institutes in Austria, Germany, Italy, France and the United Kingdom for “MitoCheck” – the largest integrated research project on cell cycle control within the European Commission’s 6th Framework Programme (FP6).

15 Jul 2004

Gene therapy may provide a treatment for a group of incurable, progressive neurological diseases called polyglutamine-repeat diseases

Researchers from the University of Iowa have have shown for the first time that gene therapy delivered to the brains of living mice can prevent the physical symptoms and neurological damage caused by an inherited neurodegenerative disease that is similar to Huntington's disease (HD).

5 Jul 2004

Lou Gehrig's disease may be treated or even prevented

Tripping, stumbling, falling, slow, steady loss of muscle control and strength in hands and feet, difficulty speaking, swallowing and breathing...

28 Jun 2004

SARS siRNA studied further to help many respiratory diseases including lung cancer

Intradigm Corporation, has announced achievement of prophylactic and therapeutic effects of siRNA (small interfering RNA) inhibitors of SARS-CoV in non-human primate cells. The results are published in the June 2004 issue of Antiviral Therapy (International Medical Press).

15 Jun 2004

Breakthrough in gene therapy

Despite a roller-coaster ride of ups and downs during the past 15 years, gene therapy has continued to attract many of the world's brightest scientists. They are tantalized by the enormous potential that replacing missing genes or disabling defective ones offers for curing diseases of many kinds.

3 Jun 2004

Novel molecular targeting technologies to deliver gene-silencing therapy

Researchers have combined novel molecular targeting technologies to deliver gene-silencing therapy specifically to tumor cells shielded by a normally impermeable obstacle, the blood brain barrier.

1 Jun 2004

Benitec acquires Avocel to focus on rapid development of hepatitis C therapeutics

Benitec Ltd. today announced the acquisition of Avocel, Inc. of Sunnyvale, CA, a leading RNAi therapeutics company, and the establishment of its wholly-owned US subsidiary, Benitec, Inc. Through the acquisition, Benitec gains its first in-house advanced therapeutic development program using DNA-directed RNAi (ddRNAi) to target the Hepatitis C virus.

18 May 2004